Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19204534 | GENE DELIVERY SYSTEM AND APPLICATION THEREOF IN PREPARATION OF DRUGS FOR TREATMENT OF TUMORS | May 2025 | January 2026 | Allow | 8 | 1 | 1 | No | No |
| 19061632 | BISPECIFIC STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | February 2025 | June 2025 | Allow | 4 | 0 | 0 | No | No |
| 18975168 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | December 2024 | September 2025 | Abandon | 9 | 1 | 0 | No | No |
| 18751743 | PHOSPHOR-CONTAINING DRUG ACTIVATOR KIT | June 2024 | September 2025 | Abandon | 15 | 2 | 0 | No | No |
| 18750610 | STEM CELL-NANO DRUG DELIVERY SYSTEM COMPLEX, USE THEREOF AND METHOD FOR PREPARING THE SAME | June 2024 | January 2026 | Allow | 19 | 3 | 0 | No | No |
| 18692203 | COSMETIC AND DETERGENT COMPOSITION COMPRISING A POLYMERIC COMPOSITION OF A WATER-SOLUBLE POLYMER ENVELOPED WITHIN ANOTHER POLYMER | March 2024 | February 2025 | Abandon | 11 | 1 | 1 | No | No |
| 18593245 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | March 2024 | October 2025 | Allow | 20 | 3 | 0 | No | No |
| 18520628 | METHOD FOR MAKING SUPERPARAMAGNETIC IRON OXIDE NANOCARRIER | November 2023 | January 2025 | Allow | 14 | 1 | 0 | No | No |
| 18491647 | METHODS OF ORIENTING MULTIFILAMENT YARN AND MONOFILAMENTS OF POLY-4-HYDROXYBUTYRATE AND COPOLYMERS THEREOF | October 2023 | March 2025 | Allow | 17 | 0 | 1 | No | No |
| 18450737 | EQUILIBRIUM ADSORPTION METHOD FOR MAKING A SILICA NANOCARRIER SPION COMPOSITION | August 2023 | November 2023 | Allow | 3 | 1 | 0 | No | No |
| 18359223 | NANOPARTICLES COMPRISING PEPTIDES INCLUDING AN N-TERMINAL LINKER | July 2023 | April 2024 | Allow | 9 | 1 | 0 | No | No |
| 18336797 | MAGNETIC NANOPARTICLES FUNCTIONALIZED WITH N-(3,4-DIHYDROXYPHENETHYL)DODECANAMIDE, PRODUCTION AND USE THEREOF | June 2023 | April 2025 | Allow | 22 | 1 | 1 | No | No |
| 18310234 | CATIONIC NANOSTRUCTURES FOR INTRA-CARTILAGE DELIVERY OF CONTRAST AGENTS AND DIAGNOSTIC USES THEREOF | May 2023 | October 2025 | Allow | 30 | 2 | 2 | No | No |
| 18131810 | Selectively Polymerizable Compositions and Methods of Use in Vivo | April 2023 | June 2025 | Abandon | 27 | 2 | 0 | No | No |
| 18296642 | COMPLEXES FOR DELIVERY OF ANTIGENIC PEPTIDES | April 2023 | February 2026 | Allow | 34 | 4 | 0 | No | No |
| 18193959 | BIOARTIFICIAL PANCREAS | March 2023 | December 2023 | Allow | 8 | 1 | 0 | No | No |
| 18190819 | MODIFIED OLIGONUCLEOTIDES | March 2023 | December 2024 | Allow | 21 | 3 | 1 | Yes | No |
| 18183328 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | March 2023 | December 2023 | Allow | 9 | 1 | 0 | No | No |
| 18183305 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | March 2023 | August 2025 | Abandon | 29 | 4 | 0 | No | No |
| 18118650 | PROTOCOL FOR MINIMIZING TOXICITY OF COMBINATION DOSAGES AND IMAGING AGENT FOR VERIFICATION | March 2023 | March 2025 | Abandon | 25 | 1 | 0 | No | No |
| 18114168 | DRUG DELIVERY AGENTS FOR PREVENTION OR TREATMENT OF PULMONARY DISEASE | February 2023 | September 2025 | Abandon | 30 | 1 | 0 | No | No |
| 18165774 | FACTOR VIII ZWITTERIONIC POLYMER CONJUGATES | February 2023 | September 2024 | Allow | 20 | 2 | 0 | No | No |
| 17987655 | MODIFIED RELEASE PREPARATIONS CONTAINING OXCARBAZEPINE AND DERIVATIVES THEREOF | November 2022 | July 2023 | Abandon | 8 | 1 | 0 | No | No |
| 18053618 | CONJUGATES OF ACTIVE PHARMACEUTICAL INGREDIENTS | November 2022 | May 2024 | Abandon | 18 | 0 | 1 | No | No |
| 17981287 | BIOARTIFICIAL PANCREAS | November 2022 | March 2023 | Allow | 4 | 1 | 0 | No | No |
| 18051721 | STEM CELL DERIVED PANCREATIC ISLET DIFFERENTIATION | November 2022 | January 2024 | Allow | 14 | 1 | 1 | No | No |
| 17961445 | MULTIFUNCTIONAL NANOPARTICLES FOR THERAGNOSIS | October 2022 | February 2025 | Abandon | 29 | 0 | 1 | No | No |
| 17938155 | METHOD FOR TREATING BREAST CANCER WITH A CHEMOTHERAPEUTIC DRUG CARRIER | October 2022 | April 2023 | Allow | 6 | 1 | 0 | No | No |
| 17938150 | CURCUMINOID CHEMOTHERAPEUTIC DRUG CARRIER COMPOSITION | October 2022 | April 2023 | Allow | 6 | 1 | 0 | No | No |
| 17867025 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | July 2022 | June 2023 | Allow | 11 | 1 | 1 | No | No |
| 17782480 | Polyphosphazene drug carriers | June 2022 | May 2025 | Allow | 36 | 1 | 0 | No | No |
| 17737928 | TARGETED CONTRAST AGENTS FOR MRI OF ALPHA-SYNUCLEIN DEPOSITION | May 2022 | August 2023 | Allow | 16 | 2 | 1 | No | No |
| 17734484 | MICROBUBBLE-CHEMOTHERAPEUTIC AGENT COMPLEX FOR SONODYNAMIC THERAPY | May 2022 | October 2025 | Allow | 41 | 1 | 0 | No | No |
| 17708253 | Gold-Platinum Based Bi-Metallic Nanocrystal Suspensions, Electrochemical Manufacturing Processes Therefor and Uses for the Same | March 2022 | December 2023 | Abandon | 20 | 1 | 0 | No | No |
| 17697692 | BIOARTIFICIAL PANCREAS | March 2022 | October 2022 | Allow | 7 | 2 | 0 | Yes | No |
| 17697694 | LYMPH DIRECTING PRODRUGS | March 2022 | November 2024 | Abandon | 32 | 2 | 0 | No | No |
| 17586495 | PHARMACEUTICAL COMPOSITION COMPRISING A POLYMER-POLYEPTIDE CONJUGATE | January 2022 | April 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17580988 | THERMORESPONSIVE HYDROGEL CONTAINING POLYMER MICROPARTICLES FOR NONINVASIVE OCULAR DRUG DELIVERY | January 2022 | April 2025 | Allow | 39 | 4 | 1 | No | No |
| 17310020 | GOLD/QUANTUM DOT NANOPROBE FOR DETECTING ACTIVE RICIN IN COMPLEX MATRIX AND APPLICATION THEREOF | January 2022 | May 2022 | Allow | 10 | 2 | 0 | Yes | No |
| 17643734 | CHELATING PLATFORM FOR DELIVERY OF RADIONUCLIDES | December 2021 | October 2024 | Allow | 34 | 1 | 1 | Yes | No |
| 17596496 | NANOPARTICLES PRE-FUNCTIONALIZED USING A SELF-ASSEMBLED MONOLAYER AND METHOD FOR PREPARING SAME | December 2021 | October 2023 | Allow | 22 | 2 | 0 | No | Yes |
| 17538770 | PHOSPHOR-CONTAINING DRUG ACTIVATOR, SUSPENSION THEREOF, SYSTEM CONTAINING THE SUSPENSION, AND METHODS FOR USE | November 2021 | June 2024 | Allow | 30 | 2 | 0 | Yes | No |
| 17535385 | MULTI-ARM POLYMER PRODRUGS | November 2021 | October 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17611062 | COMPOSITIONS AND METHODS FOR INHIBITING NUCLEIC ACID VECTOR-INDUCED INFLAMMATORY RESPONSES | November 2021 | November 2025 | Abandon | 48 | 0 | 1 | No | No |
| 17523442 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | November 2021 | October 2023 | Abandon | 24 | 4 | 0 | No | No |
| 17523628 | TAG FOR LABELING BIOMOLECULES | November 2021 | October 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17608911 | NANOEMULSION WITH PORPHYRIN SHELL | November 2021 | February 2026 | Allow | 51 | 4 | 0 | Yes | No |
| 17511769 | FORMATION AND USES OF EUROPIUM | October 2021 | July 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17484175 | DENDRIMER COMPOSITIONS AND USE IN TREATMENT OF NECROTIZING ENTEROCOLITIS AND OTHER GASTROINTESTINAL DISORDERS | September 2021 | March 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17411117 | METHOD FOR MAKING HYDROGEL MARKERS | August 2021 | November 2025 | Abandon | 50 | 2 | 1 | No | Yes |
| 17383821 | MODIFIED PLANT MESSENGER PACKS AND USES THEREOF | July 2021 | September 2025 | Abandon | 49 | 7 | 0 | No | No |
| 17421320 | METHODS FOR IMAGING AND TREATING DAMAGED CARTILAGE | July 2021 | October 2025 | Abandon | 51 | 3 | 0 | No | No |
| 17348911 | NANOSILICA CARRIER WITH SPIONS AND A CURCUMINOID | June 2021 | July 2023 | Allow | 25 | 1 | 0 | No | No |
| 17339074 | LOADABLE POLYMERIC PARTICLES FOR THERAPEUTIC AND/OR DIAGNOSTIC APPLICATIONS AND METHODS OF PREPARING AND USING THE SAME | June 2021 | October 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17334673 | GREEN TECHNOLOGY FOR CROSSLINKING PROTEIN MOLECULES FOR VARIOUS USES | May 2021 | December 2023 | Allow | 31 | 2 | 0 | Yes | No |
| 17297924 | NOVEL TETRAZINE COMPOUNDS FOR IN VIVO IMAGING | May 2021 | February 2026 | Allow | 57 | 2 | 1 | No | No |
| 17294914 | CONJUGATES OF BIVALENT EVANS BLUE DYE DERIVATIVES AND METHODS OF USE | May 2021 | February 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17238796 | MODIFIED RELEASE PREPARATIONS CONTAINING OXCARBAZEPINE AND DERIVATIVES THEREOF | April 2021 | September 2021 | Allow | 5 | 2 | 0 | No | No |
| 17229013 | Gold-Based Nanocrystals for Medical Treatments and Electrochemical Manufacturing Processes Therefor | April 2021 | April 2025 | Abandon | 48 | 2 | 1 | No | No |
| 17223336 | NOVEL GOLD-BASED NANOCRYSTALS FOR MEDICAL TREATMENTS AND ELECTROCHEMICAL MANUFACTURING PROCESSES THEREFOR | April 2021 | November 2024 | Abandon | 44 | 1 | 2 | No | No |
| 17208368 | STRUCTURE THAT COMPRESSES OR EXPANDS A VOLUME IN RESPONSE TO AN APPLIED MAGNETIC FIELD | March 2021 | November 2024 | Abandon | 44 | 2 | 1 | No | Yes |
| 17198037 | COMPOSITIONS AND METHODS FOR MODIFIED DENDRIMER NANOPARTICLE DELIVERY | March 2021 | April 2025 | Allow | 49 | 4 | 1 | No | Yes |
| 17185217 | Once Daily Formulations Of Tetracyclines | February 2021 | November 2022 | Abandon | 20 | 1 | 0 | No | No |
| 17175359 | TARGETED CONTRAST AGENTS FOR MRI OF ALPHA-SYNUCLEIN DEPOSITION | February 2021 | July 2023 | Abandon | 29 | 0 | 0 | No | No |
| 17175394 | SELECTIVE DENDRIMER DELIVERY TO BRAIN TUMORS | February 2021 | March 2026 | Abandon | 60 | 6 | 0 | No | No |
| 17172793 | COMPOSITIONS AND METHODS OF MAKING POLYMERIZED NUCLEIC ACIDS | February 2021 | May 2024 | Allow | 39 | 1 | 2 | No | No |
| 17265790 | MULTIFUNCTIONAL NANOPARTICLES FOR THERAGNOSIS | February 2021 | October 2022 | Abandon | 20 | 0 | 1 | No | No |
| 17162338 | TARGETED CONTRAST AGENTS FOR MRI OF AMYLOID DEPOSITION | January 2021 | October 2022 | Abandon | 21 | 1 | 0 | No | No |
| 17263456 | BIOMARKERS AND USES THEREOF | January 2021 | March 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 17263115 | BEADED NONWOVEN MEMBRANE AS A DRUG DELIVERY SYSTEM | January 2021 | March 2025 | Allow | 49 | 4 | 0 | No | Yes |
| 17152344 | Microtubule-associated protein Tau imaging compounds for Alzheimer's disease and precursors thereof | January 2021 | October 2024 | Abandon | 45 | 0 | 1 | No | No |
| 17123808 | MAGNETIC NANOPARTICLES FUNCTIONALIZED WITH CATECHOL, PRODUCTION AND USE THEREOF | December 2020 | June 2023 | Abandon | 30 | 2 | 0 | No | No |
| 17108403 | DRUG DELIVERY AGENTS FOR PREVENTION OR TREATMENT OF PULMONARY DISEASE | December 2020 | March 2023 | Abandon | 27 | 2 | 0 | No | No |
| 15733835 | COMPOSITIONS AND METHODS FOR IMAGING | November 2020 | August 2024 | Allow | 44 | 2 | 1 | No | No |
| 17058037 | SCREENING ASSAY TO ASSESS TOPICAL DELIVERY OF BIOLOGICAL THERAPEUTIC AGENTS | November 2020 | April 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17098328 | Transdermal Delivery System | November 2020 | January 2026 | Abandon | 60 | 6 | 2 | Yes | No |
| 17093186 | CATIONIC NANOSTRUCTURES FOR INTRA-CARTILAGE DELIVERY OF THERAPEUTICS AND CONTRAST AGENTS | November 2020 | July 2023 | Abandon | 32 | 2 | 1 | No | No |
| 17087439 | POTASSIUM-BINDING AGENTS FOR TREATING HYPERTENSION AND HYPERKALEMIA | November 2020 | December 2025 | Abandon | 60 | 8 | 0 | Yes | Yes |
| 17081383 | MODIFIED RELEASE PREPARATIONS CONTAINING OXCARBAZEPINE AND DERIVATIVES THEREOF | October 2020 | July 2024 | Abandon | 45 | 11 | 0 | Yes | Yes |
| 17049759 | METHODS OF ENHANCING IMMUNOGENICITY OF POORLY IMMUNOGENIC ANTIGEN-SPECIFIC VACCINES USING ORAL YEAST BETA-GLUCANS | October 2020 | March 2025 | Allow | 53 | 3 | 1 | Yes | No |
| 17049848 | ANTIBACTERIAL GLASS COMPOSITION AND METHOD FOR PREPARING SAME | October 2020 | December 2025 | Allow | 60 | 4 | 1 | No | No |
| 17076687 | STATIN-CONTAINING NANOPARTICLE PREPARATION FOR ENHANCING FUNCTION OF STEM CELLS FOR TREATING INFLAMMATORY DISEASE, AND FUNCTIONALLY ENHANCED STEM CELLS CONTAINING SAME FOR TREATING INFLAMMATORY DISEASE | October 2020 | August 2022 | Abandon | 22 | 1 | 0 | No | No |
| 17047647 | NANOPARTICLES FOR BORON NEUTRON CAPTURE THERAPY AND FOR DIAGNOSING, DETECTING, AND TREATING CANCER | October 2020 | July 2022 | Abandon | 21 | 1 | 0 | No | No |
| 17022073 | Promoting Immune Responses | September 2020 | September 2021 | Allow | 12 | 2 | 0 | No | No |
| 16977680 | CHEMOSELECTIVE THIOL-CONJUGATION WITH ALKENE OR ALKYNE-PHOSPHONOTHIOLATES AND - PHOSPHONATES | September 2020 | June 2025 | Allow | 57 | 2 | 3 | No | No |
| 17008136 | CU(I)-CATALYZED AZIDE-ALKYNE CYCLOADDITIONS (CUAAC) LIGANDS AND METHODS FOR CARRYING OUT CU(I)-CATALYZED AZIDE-ALKYNE CYCLOADDITION REACTIONS | August 2020 | July 2021 | Allow | 10 | 2 | 0 | No | No |
| 16962946 | LITHIUM FLUORIDE NANOPARTICLES FOR THE PROTECTION OF CHONDROCYTES IN OSTEOARTHRITIS | July 2020 | July 2023 | Abandon | 36 | 3 | 0 | No | No |
| 16932369 | NANOCAPSULE FOR DELIVERY OF LIPOPHILIC COMPOUND AND PROCESS OF PREPARATION THEREOF | July 2020 | November 2023 | Abandon | 40 | 4 | 1 | No | No |
| 16961349 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE,PREPARATION METHOD THEREFOR, AND USES THEREOF | July 2020 | November 2025 | Allow | 60 | 8 | 1 | Yes | No |
| 16961403 | PHOSPHOALKYL POLYMERS COMPRISING BIOLOGICALLY ACTIVE AGENTS | July 2020 | September 2025 | Allow | 60 | 3 | 1 | Yes | No |
| 16961633 | PROTOCOL FOR MINIMIZING TOXICITY OF COMBINATION DOSAGES AND IMAGING AGENT FOR VERIFICATION | July 2020 | May 2023 | Abandon | 34 | 2 | 1 | No | No |
| 16958045 | IL-2 VARIANT | June 2020 | December 2024 | Allow | 54 | 2 | 1 | No | No |
| 16898047 | Gel for Acoustic Coupler, Method for Producing the Same, and Ultrasonic Imaging Method | June 2020 | January 2025 | Abandon | 55 | 2 | 1 | No | No |
| 16771587 | ENGINEERED EXTRACELLULAR VESICLES FOR ENHANCED TISSUE DELIVERY | June 2020 | January 2023 | Allow | 31 | 2 | 0 | No | No |
| 16771185 | IONIC POLYMERS COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS | June 2020 | July 2025 | Abandon | 60 | 3 | 1 | No | No |
| 16891823 | TOPICALLY APPLICABLE PHARMACEUTICAL PREPARATION | June 2020 | March 2023 | Abandon | 33 | 2 | 0 | No | No |
| 16886927 | TARGETED ANTIMICROBIAL PHOTODYNAMIC THERAPY | May 2020 | July 2022 | Abandon | 26 | 4 | 0 | No | No |
| 16878401 | CONJUGATES HAVING A DEGRADABLE LINKAGE AND POLYMERIC REAGENTS USEFUL IN PREPARING SUCH CONJUGATES | May 2020 | October 2021 | Allow | 17 | 0 | 0 | No | No |
| 16877141 | METHODS FOR DISTRIBUTING AGENTS TO AREAS OF BRAIN | May 2020 | December 2022 | Abandon | 31 | 2 | 1 | No | No |
| 16764492 | Polymeric prodrugs and subcutaneous and/or intramuscular administration thereof | May 2020 | March 2024 | Allow | 46 | 5 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DICKINSON, PAUL W.
With a 35.7% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 25.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner DICKINSON, PAUL W works in Art Unit 1618 and has examined 1,119 patent applications in our dataset. With an allowance rate of 61.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.
Examiner DICKINSON, PAUL W's allowance rate of 61.8% places them in the 22% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by DICKINSON, PAUL W receive 2.26 office actions before reaching final disposition. This places the examiner in the 63% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by DICKINSON, PAUL W is 36 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +11.5% benefit to allowance rate for applications examined by DICKINSON, PAUL W. This interview benefit is in the 46% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 23.5% of applications are subsequently allowed. This success rate is in the 32% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 22.8% of cases where such amendments are filed. This entry rate is in the 30% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 64.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 52% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 61.1% of appeals filed. This is in the 38% percentile among all examiners. Of these withdrawals, 54.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 73.0% are granted (fully or in part). This grant rate is in the 79% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 3.8% of allowed cases (in the 82% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.